HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM THE PHASE 3 CANDOR STUDY COMPARING CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB TO CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA D.S. Siegel, K. Weisel, A. Zahlten-Kumeli, R. Medhekar, S. Sapra, B. Ding, X. Leleu

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES H. Quach, A. Nooka, O. Samoylova, C.P. Venner, T. Facon, A. Spencer, S.Z. Usmani, K. Weisel, M. Mateos, K. Kim, S. Grosicki, K. Suzuki, S. Delimpasi, M. Obreja, A. Zahlten-Kumeli

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma C. Cerchione, L. Catalano, D. Nappi, G. Musuraca, A. Lucchesi, S. Ronconi, F. Pane, G. Martinelli